Patents Assigned to Raptor Pharmaceutical Inc.
  • Receptor associated protein (RAP) conjugates
    Patent number: 7829537
    Abstract: The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: November 9, 2010
    Assignee: Raptor Pharmaceuticals Inc.
    Inventors: Todd C. Zankel, Christopher M. Starr
  • CYCLIC RECEPTOR-ASSOCIATED PROTEIN (RAP) PEPTIDES
    Publication number: 20100210517
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Application
    Filed: March 21, 2008
    Publication date: August 19, 2010
    Applicant: Raptor Pharmaceutical Inc.
    Inventors: Christopher M. Starr, Todd C. Zankel
  • Compositions and Methods for Modulating Blood-Brain Barrier Transport
    Publication number: 20100183581
    Abstract: This invention provides conjugates of therapeutic or active agents with melanotransferrin or with other ligands of a melanotransferrin receptor, melanotransferrin receptor modulators, and related compositions and methods for modulating blood-brain barrier transport by providing methods of screening and selecting such conjugates, ligands, and modulators in vitro and in vivo, and methods of use of such conjugates, modulators and ligands in diagnosis and the treatment of diseases, including particularly diseases of the central nervous system or lysosomal storage diseases.
    Type: Application
    Filed: January 7, 2010
    Publication date: July 22, 2010
    Applicant: RAPTOR PHARMACEUTICAL INC.
    Inventors: Richard Beliveau, Michel Demeule, Joseph Yang, Malcolm L. Kennard, Reinhard Gabathuler
  • Compositions for modulating blood-brain barrier transport
    Patent number: 7700554
    Abstract: This invention provides conjugates of therapeutic or active agents with melanotransferrin or with other ligands of a melanotransferrin receptor, melanotransferrin receptor modulators, and related compositions and methods for modulating blood-brain barrier transport by providing methods of screening and selecting such conjugates, ligands, and modulators in vitro and in vivo, and methods of use of such conjugates, modulators and ligands in diagnosis and the treatment of diseases, including particularly diseases of the central nervous system or lysosomal storage diseases.
    Type: Grant
    Filed: October 13, 2006
    Date of Patent: April 20, 2010
    Assignee: Raptor Pharmaceuticals Inc.
    Inventors: Richard Beliveau, Michel Demeule, Joseph Yang, Malcolm L. Kennard, Reinhard Gabathuler
  • MEGALIN-BASED DELIVERY OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUES
    Publication number: 20100028370
    Abstract: The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.
    Type: Application
    Filed: July 24, 2009
    Publication date: February 4, 2010
    Applicant: RAPTOR PHARMACEUTICAL INC.
    Inventors: TODD ZANKEL, Christopher M. Starr
  • Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for CR-Containing Proteins and Uses Thereof
    Publication number: 20090281024
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes.
    Type: Application
    Filed: September 18, 2006
    Publication date: November 12, 2009
    Applicant: RAPTOR PHARMACEUTICAL INC.
    Inventors: Todd C. Zankel, Christopher M. Starr
  • Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for LRP2 and Uses Thereof
    Publication number: 20090269346
    Abstract: The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. The invention also relates to antibodies that bind to one or a small subset of CR-containing proteins.
    Type: Application
    Filed: June 14, 2006
    Publication date: October 29, 2009
    Applicant: RAPTOR PHARMACEUTICAL INC.
    Inventors: Christopher M. Starr, Todd C. Zankel
  • Methods of increasing delivery of active agents to brain comprising administering receptor associated protein (RAP) fragments conjugated to active agents
    Patent number: 7569544
    Abstract: The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.
    Type: Grant
    Filed: March 30, 2004
    Date of Patent: August 4, 2009
    Assignee: Raptor Pharmaceutical Inc.
    Inventors: Todd Zankel, Christopher M. Starr
  • Methods of increasing delivery of active agents to brain comprising administering receptor associated protein (RAP) fragments conjugated to active agents
    Patent number: 7560431
    Abstract: This invention provides compounds of conjugates of therapeutic or active agents with RAP or a RAP polypeptide, their pharmaceutical compositions and methods for using the such compounds and compositions in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly diseases of the central nervous system or lysosomal storage diseases.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: July 14, 2009
    Assignee: Raptor Pharmaceutical Inc.
    Inventors: Todd Zankel, Christopher M. Starr, Reinhard Gabathuler